Depletion of tumor associated macrophages enhances local and systemic platelet-mediated anti-PD-1 delivery for post-surgery tumor recurrence treatment

• Published in: Nature communications 2022-04, Vol.13 (1), p.1845-1845, Article 1845
• Main Authors: Li, Zhaoting, Ding, Yingyue, Liu, Jun, Wang, Jianxin, Mo, Fanyi, Wang, Yixin, Chen-Mayfield, Ting-Jing, Sondel, Paul M., Hong, Seungpyo, Hu, Quanyin
• Format: Article
• Language: English
• Subjects: 13; 13/1; 13/106; 13/21; 13/31; 14/19; 14/34; 14/5; 631/61/54/152; 631/67/1059/2325; 692/4028/67/580; Alginates; Alginic acid; Antibodies; Apoptosis; Biocompatibility; Blood Platelets; Cell activation; Cell death; Cell-Derived Microparticles; Colony-stimulating factor; Depletion; Encapsulation; Humanities and Social Sciences; Humans; Hydrogels; Immune checkpoint; Immunotherapy - methods; Infiltration; Inflammation; Lymphocytes; Lymphocytes T; Macrophage colony-stimulating factor; Macrophages; Metastases; Microparticles; multidisciplinary; Nanoparticles; Neoplasm Recurrence, Local; PD-1 protein; Platelets; Receptors; Science; Science (multidisciplinary); Surgery; Tumor Microenvironment; Tumor-Associated Macrophages; Tumors
• ISSN: 2041-1723; 2041-1723
• DOI: 10.1038/s41467-022-29388-0

Immunosuppressive cells residing in the tumor microenvironment, especially tumor associated macrophages (TAMs), hinder the infiltration and activation of T cells, limiting the anti-cancer outcomes of immune checkpoint blockade. Here, we report a biocompatible alginate-based hydrogel loaded with Pexidartinib (PLX)-encapsulated nanoparticles that gradually release PLX at the tumor site to block colony-stimulating factor 1 receptors (CSF1R) for depleting TAMs. The controlled TAM depletion creates a favorable milieu for facilitating local and systemic delivery of anti-programmed cell death protein 1 (aPD-1) antibody-conjugated platelets to inhibit post-surgery tumor recurrence. The tumor immunosuppressive microenvironment is also reprogrammed by TAM elimination, further promoting the infiltration of T cells into tumor tissues. Moreover, the inflammatory environment after surgery could trigger the activation of platelets to facilitate the release of aPD-1 accompanied with platelet-derived microparticles binding to PD-1 receptors for re-activating T cells. All these results collectively indicate that the immunotherapeutic efficacy against tumor recurrence of both local and systemic administration of aPD-1 antibody-conjugated platelets could be strengthened by local depletion of TAMs through the hydrogel reservoir. Increased density of tumor associated macrophages has been correlated with tumor recurrence following surgery. Here the authors design an alginate-based hydrogel encapsulating anti-PD-1-conjugated platelets and nanoparticles loaded with the macrophage-depleting CSF-1R inhibitor pexidartinib, showing inhibition of post-surgery tumor recurrence in preclinical models.